<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Erythromycin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00199</strong>&#160; (APRD00953)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Erythromycin is a macrolide antibiotic produced by Streptomyces erythreus. It inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits; binding inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.  Erythromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00199/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00199/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00199.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00199.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00199.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00199.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00199.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00199">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>3''-O-demethylerythromycin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Abomacetin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Erythromycin A</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Erythromycin C</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Akne-Mycin</td><td>Almirall Hermal</td></tr><tr><td>E.E.S</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>E.E.S.</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ery</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ery-Ped</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>ERY-TAB</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Eryc</td><td>Hospira</td></tr><tr><td>Erygel</td><td>Merz</td></tr><tr><td>Erythra-Derm</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ilosone</td><td>Cipa</td></tr><tr><td>ILOTYCIN</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Staticin</td><td>Westwood</td></tr><tr><td>T-stat</td><td>Westwood</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Sans-Acne Solution</td><td>Alcohol Anhydrous + Erythromycin</td></tr><tr><td>Staticin Lot</td><td>Alcohol Anhydrous + Erythromycin + Laureth 4</td></tr><tr><td>Stievamycin Forte Gel</td><td>Erythromycin + Tretinoin</td></tr><tr><td>Stievamycin Gel</td><td>Erythromycin + Tretinoin</td></tr><tr><td>T-Stat Lot</td><td>Alcohol Anhydrous + Erythromycin</td></tr><tr><td>T-Stat Pad-Lot</td><td>Alcohol Anhydrous + Erythromycin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/gastrointestinal-agents">Gastrointestinal Agents</a></li>
<li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/protein-synthesis-inhibitors">Protein Synthesis Inhibitors</a></li>
<li><a href="/mesh/macrolides">Macrolides</a></li></ul></td></tr><tr><th>CAS number</th><td>114-07-8</td></tr><tr><th>Weight</th><td>Average: 733.9268<br>Monoisotopic: 733.461241235</td></tr><tr><th>Chemical Formula</th><td>C<sub>37</sub>H<sub>67</sub>NO<sub>13</sub></td></tr><tr><th>InChI Key</th><td>ULGZDMOVFRHVEP-RWJQBGPGSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Macrolides and Analogues</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Macrolides and Analogues</td></tr><tr><th>Alternative parents</th><td>Dihexoses; O-glycosyl Compounds; Amino Sugars; Oxanes; Tertiary Alcohols; Tertiary Amines; Ketones; 1,2-Diols; Secondary Alcohols; Carboxylic Acid Esters; Polyamines; Acetals</td></tr><tr><th>Substituents</th><td>disaccharide; amino sugar; oxane; saccharide; tertiary alcohol; tertiary amine; 1,2-diol; secondary alcohol; carboxylic acid ester; ketone; polyol; acetal; ether; polyamine; carboxylic acid derivative; carbonyl group; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to <i>Corynebacterium diphtheriae</i>, in the treatment of infections due to <i>Corynebacterium minutissimum</i>, intestinal amebiasis caused by <i>Entamoeba histolytica</i>, acute pelvic inflammatory disease caused by <i>Neisseria gonorrhoeae</i>, skin and soft tissue infections of mild to moderate severity caused by <i>Streptococcus pyogenes</i> and <i>Staphylococcus aureus</i>, primary syphilis caused by <i>Treponema pallidum</i>, infections caused by <i>Chlamydia trachomatis</i>, nongonococcal urethritis caused by <i>Ureaplasma urealyticum</i>, and Legionnaires' disease caused by <i>Legionella pneumophila</i>.</td></tr><tr><th>Pharmacodynamics</th><td>Erythromycin is produced by a strain of Streptomyces erythraeus and belongs to the macrolide group of antibiotics. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin is excreted in breast milk. The drug crosses the placental barrier with fetal serum drug levels reaching 5 - 20% of maternal serum concentrations. Erythromycin is not removed by peritoneal dialysis or hemodialysis.</td></tr><tr><th>Mechanism of action</th><td>Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the &#8220;P&#8221; or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the &#8220;A&#8221; or acceptor site to the &#8220;P&#8221; or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.</td></tr><tr><th>Absorption</th><td>Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Topical application of the ophthalmic ointment to the eye may result in absorption into the cornea and aqueous humor.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Erythromycin is largely bound to plasma proteins, ranging from 75 - 95% binding depending on the form.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Extensively metabolized - after oral administration, less than 5% of the administered dose can be recovered in the active form in the urine. Erythromycin is partially metabolized by CYP3A4 resulting in numerous drug interactions.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Erythromycin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00365">norerythromycin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/367">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>0.8 - 3 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Erythromycin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00250?highlight%5Bcompounds%5D%5B%5D=DB00199&amp;highlight%5Bproteins%5D%5B%5D=DB00199">SMP00250</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.5114</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9889</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8098</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8564</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5963</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9222</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9225</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6528</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9074</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5744</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9391</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9335
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2296 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9902
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8956
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Hospira inc</li>
<li>Parke davis div warner lambert co</li>
<li>Warner chilcott inc</li>
<li>Abbott laboratories pharmaceutical products div</li>
<li>Barr laboratories inc</li>
<li>Stiefel laboratories inc</li>
<li>Altana inc</li>
<li>Merz pharmaceuticals llc</li>
<li>Perrigo co</li>
<li>Syosset laboratories inc</li>
<li>Akorn inc</li>
<li>Bausch and lomb pharmaceuticals inc</li>
<li>E fougera div altana inc</li>
<li>Pharmaderm div altana inc</li>
<li>Pharmafair inc</li>
<li>Dista products co div eli lilly and co</li>
<li>Dow pharmaceutical sciences inc</li>
<li>Paddock laboratories inc</li>
<li>Taro pharmaceuticals north america inc</li>
<li>Bioglan pharma inc</li>
<li>Alpharma us pharmaceuticals division</li>
<li>Eli lilly and co</li>
<li>Perrigo new york inc</li>
<li>Wockhardt eu operations (swiss) ag</li>
<li>Hi tech pharmacal co inc</li>
<li>Westwood squibb pharmaceuticals inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Orthoneutrogena</li>
<li>Versapharm inc</li>
<li>Ah robins co</li>
<li>Solvay pharmaceuticals</li>
<li>Watson laboratories inc</li>
<li>Life laboratories inc</li>
<li>Lilly research laboratories div eli lilly and co</li>
<li>Ross laboratories div abbott laboratories inc</li>
<li>Pharmacia and upjohn co</li>
<li>Naska pharmacal co inc div rugby darby group cosmetics</li>
<li>Wyeth ayerst laboratories</li>
<li>Abbott laboratories chemical and agricultural products div</li>
<li>Mylan pharmaceuticals inc</li>
<li>Elkins sinn div ah robins co inc</li>
<li>Abraxis pharmaceutical products</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Teva parenteral medicines inc</li>
<li>Bristol laboratories inc div bristol myers co</li>
<li>Warner chilcott div warner lambert co</li>
<li>Lederle laboratories div american cyanamid co</li>
<li>Purepac pharmaceutical co</li>
<li>Bristol myers squibb co</li>
<li>Pfizer laboratories div pfizer inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.bausch.com">Bausch &amp; Lomb Inc.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Carlisle Laboratories Inc.</li>
<li>Casa De Amigos Pharmacy</li>
<li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Community Action Inc. Community Health Services</li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.contractpharma.com">Contract Pharm</a></li>
<li><a href="http://www.corepharma.com">Core Pharmaceuticals</a></li>
<li><a href="http://www.corialabs.com">Coria Laboratories</a></li>
<li><a href="http://www.darbydental.com">Darby Dental Supply Co. Inc.</a></li>
<li>Dept Health Central Pharmacy</li>
<li>Dermik Labs</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.dptlabs.com">DPT Laboratories Ltd.</a></li>
<li>DRX Pharmaceuticals</li>
<li><a href="http://www.fougera.com">E. Fougera and Co.</a></li>
<li><a href="http://www.lilly.com">Eli Lilly &amp; Co.</a></li>
<li><a href="http://www.eyecareandcure.com">Eye Care and Cure Corp.</a></li>
<li><a href="http://www.eyesupplyusa.com">Eye Supply Usa Inc.</a></li>
<li><a href="http://www.ferapharma.com">Fera Pharmaceuticals</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Inyx Usa Ltd.</li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.maynepharma.com">Mayne Pharma International Pty Ltd.</a></li>
<li>Medical Ophthalmics</li>
<li><a href="http://www.medicis.com">Medicis Pharmaceutical Co.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.merz.com">Merz Pharmaceuticals LLC</a></li>
<li><a href="http://www.msdh.state.ms.us">Mississippi State Dept Health</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mwivet.com">MWI Veterinary Supply Co.</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.nycomed.com">Nycomed Inc.</a></li>
<li><a href="http://www.ocusoft.com">Ocusoft</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.paddocklabs.com">Paddock Labs</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.patientfirst.com">Patient First Corp.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li>Pharmaceutical Corporation of America</li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.pharmaderm.com">Pharmaderm</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.pharmpakinc.com">Pharmpak Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.polfa.pl">Polfa</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Prescription Dispensing Service Inc.</li>
<li>Proter SPA</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li>Seneca Pharmaceuticals Inc.</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tolmar.com">Tolmar Inc.</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li>
<li>Veratex Corp.</li>
<li>Wa Butler Co.</li>
<li><a href="http://www.hilco.com">Wilson Ophthalmic Corp.</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li>
<li><a href="http://www.x-gen.us">X-Gen Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, coated</td><td>Oral</td><td></td></tr><tr><td>Liquid</td><td>Dental</td><td></td></tr><tr><td>Liquid</td><td>Oral</td><td></td></tr><tr><td>Ointment</td><td>Ophthalmic</td><td></td></tr><tr><td>Powder</td><td>Intravenous</td><td></td></tr><tr><td>Powder</td><td>Oral</td><td></td></tr><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr><tr><td>Powder, for solution</td><td>Oral</td><td></td></tr><tr><td>Powder, for suspension</td><td>Oral</td><td></td></tr><tr><td>Suspension</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Benzamycin 5-3% Gel 46.6 gm Jar</td><td>236.63USD</td><td>jar</td></tr><tr><td>BenzamycinPak 60 5-3% Packets (2 Box Contains 60 Packets)</td><td>142.45USD</td><td>packet</td></tr><tr><td>Erythromycin 2% Gel 60 gm Tube</td><td>46.8USD</td><td>tube</td></tr><tr><td>Erycette 60 2% Pad Box</td><td>30.99USD</td><td>box</td></tr><tr><td>Erythromycin 2% Gel 30 gm Tube</td><td>26.2USD</td><td>tube</td></tr><tr><td>Erythromycin 2% Solution 60ml Bottle</td><td>26.13USD</td><td>bottle</td></tr><tr><td>Eryderm 2% Solution 60ml Bottle</td><td>25.99USD</td><td>bottle</td></tr><tr><td>Erythromycin 5 mg/gm Ointment Limited Supply Available.</td><td>13.99USD</td><td>tube</td></tr><tr><td>Benzamycin gel</td><td>4.95USD</td><td>g</td></tr><tr><td>Akne-mycin 2% ointment</td><td>3.96USD</td><td>g</td></tr><tr><td>PCE 500 mg Enteric Coated Tabs</td><td>3.28USD</td><td>tab</td></tr><tr><td>Pce 500 mg dispertab</td><td>3.03USD</td><td>tablet</td></tr><tr><td>PCE 333 mg Enteric Coated Tabs</td><td>2.48USD</td><td>tab</td></tr><tr><td>Erythromycin e.s. powder</td><td>2.39USD</td><td>g</td></tr><tr><td>Benzamycinpak gel</td><td>2.37USD</td><td>gel</td></tr><tr><td>Pce 333 mg dispertab</td><td>2.3USD</td><td>tablet</td></tr><tr><td>Romycin eye ointment</td><td>1.98USD</td><td>g</td></tr><tr><td>Erythromycin eye ointment</td><td>1.44USD</td><td>g</td></tr><tr><td>Pms-Erythromycin 0.5 % Ointment</td><td>1.3USD</td><td>g</td></tr><tr><td>Emgel 2% topical gel</td><td>1.07USD</td><td>g</td></tr><tr><td>Ery-Tab 500 mg Enteric Coated Tabs</td><td>0.93USD</td><td>tab</td></tr><tr><td>Ery-tab 500 mg tablet ec</td><td>0.77USD</td><td>tablet</td></tr><tr><td>Ery-Tab 333 mg Enteric Coated Tabs</td><td>0.72USD</td><td>tab</td></tr><tr><td>Erythro-rx powder</td><td>0.72USD</td><td>g</td></tr><tr><td>Erythromycin ec 500 mg tablet</td><td>0.66USD</td><td>tablet</td></tr><tr><td>Erythromycin Base 500 mg tablet</td><td>0.61USD</td><td>tablet</td></tr><tr><td>Eryc 333 mg Capsule (Enteric-Coated Pellet)</td><td>0.6USD</td><td>capsule</td></tr><tr><td>Apo-Erythro-S 500 mg Tablet</td><td>0.57USD</td><td>tablet</td></tr><tr><td>E-mycin 333 mg tablet ec</td><td>0.54USD</td><td>tablet</td></tr><tr><td>Eryc 250 mg Capsule (Enteric-Coated Pellet)</td><td>0.54USD</td><td>capsule</td></tr><tr><td>Erythromycin powder</td><td>0.54USD</td><td>g</td></tr><tr><td>Erythromycin 2% gel</td><td>0.5USD</td><td>g</td></tr><tr><td>Erythromycin Base 250 mg Enteric Coated Capsule</td><td>0.5USD</td><td>capsule</td></tr><tr><td>Erythromycin Base 250 mg tablet</td><td>0.5USD</td><td>tablet</td></tr><tr><td>Ery-tab ec 500 mg tablet</td><td>0.46USD</td><td>tablet</td></tr><tr><td>Apo-Erythro E-C 333 mg Capsule (Enteric-Coated Pellet)</td><td>0.45USD</td><td>capsule</td></tr><tr><td>Ery-Tab 250 mg Enteric Coated Tabs</td><td>0.45USD</td><td>tab</td></tr><tr><td>Erythromycin st 500 mg tablet</td><td>0.44USD</td><td>tablet</td></tr><tr><td>Apo-Erythro E-C 250 mg Capsule (Enteric-Coated Pellet)</td><td>0.41USD</td><td>capsule</td></tr><tr><td>Ery-tab 333 mg tablet ec</td><td>0.4USD</td><td>tablet</td></tr><tr><td>Apo-Erythro-Es 600 mg Tablet</td><td>0.35USD</td><td>tablet</td></tr><tr><td>Erythromycin 500 mg filmtab</td><td>0.3USD</td><td>tablet</td></tr><tr><td>Erythrocin 500 mg filmtab</td><td>0.29USD</td><td>tablet</td></tr><tr><td>Ery-tab 250 mg tablet ec</td><td>0.27USD</td><td>tablet</td></tr><tr><td>E.e.s. 400 filmtab</td><td>0.25USD</td><td>tablet</td></tr><tr><td>Erythromycin 250 mg filmtab</td><td>0.25USD</td><td>tablet</td></tr><tr><td>Erythromycin es 400 mg tablet</td><td>0.25USD</td><td>tablet</td></tr><tr><td>Apo-Erythro-S 250 mg Tablet</td><td>0.22USD</td><td>tablet</td></tr><tr><td>Apo-Erythro Base 250 mg Tablet</td><td>0.19USD</td><td>tablet</td></tr><tr><td>Erythrocin 250 mg filmtab</td><td>0.16USD</td><td>tablet</td></tr><tr><td>Novo-Rythro Ees 80 mg/ml Suspension</td><td>0.15USD</td><td>ml</td></tr><tr><td>Novo-Rythro Estolate 50 mg/ml Suspension</td><td>0.13USD</td><td>ml</td></tr><tr><td>Novo-Rythro Ees 40 mg/ml Suspension</td><td>0.1USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>191 &#176;C</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>2000mg/L at 28&#176;C</td><td>European Pharmacopeia</td></tr><tr><td>logP</td><td>3.06</td><td>MCFARLAND,JW ET AL. (1997)</td></tr><tr><td>Caco2 permeability</td><td>-5.43</td><td>ADME Research, USCD</td></tr><tr><td>pKa</td><td>8.88 (at 25 &#176;C)</td><td>MCFARLAND,JW ET AL. (1997)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>4.59e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.37</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>12.44</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>8.38</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>13</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>193.91</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>186.04</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>78.21</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Takehiro Amano, Masami Goi, Kazuto Sekiuchi, Tomomichi Yoshida, Masahiro Hasegawa, &#8220;Process for preparing erythromycin A oxime or a salt thereof.&#8221; U.S. Patent US5274085, issued October, 1966.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5274085&amp;tbm=pts" target="_blank">US5274085 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Kanazawa S, Ohkubo T, Sugawara K: The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):799-803. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11294369">Pubmed</a></li>
	<li>Ogwal S, Xide TU: Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci. 2001 Dec;1(2):90-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12789122">Pubmed</a></li>
	<li>Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007 Jul;47(7):871-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17585116">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00140" target="_blank">D00140 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C01912" target="_blank">C01912 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=12560" target="_blank">12560 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508487" target="_blank">46508487 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.12041.html" target="_blank">12041 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=48923" target="_blank">48923 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL532" target="_blank">CHEMBL532 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000111" target="_blank">DAP000111 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449493" target="_blank">PA449493 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>HET</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/msd-srv/chempdb/cgi-bin/cgi.pl?FUNCTION=getByCode&amp;CODE=ERY" target="_blank">ERY <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2237041" target="_blank">2237041 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/erithrom.htm" target="_blank">http://www.rxlist.com/cgi/generic/erithrom.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/erythromycin-ointment.html" target="_blank">http://www.drugs.com/cdi/erythromycin-ointment.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ery1163.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ery1163.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Erythromycin" target="_blank">Erythromycin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>D10AF02<ul class="atc-drug-tree"><li><a href="/atc/D#D">D &#8212; DERMATOLOGICALS</a></li><li><a href="/atc/D10#D10">D10 &#8212; ANTI-ACNE PREPARATIONS</a></li><li><a href="/atc/D10A#D10A">D10A &#8212; ANTI-ACNE PREPARATIONS FOR TOPICAL USE</a></li><li><a href="/atc/D10AF#D10AF">D10AF &#8212; Antiinfectives for treatment of acne</a></li></ul>J01FA01<ul class="atc-drug-tree"><li><a href="/atc/J#J">J &#8212; ANTIINFECTIVES FOR SYSTEMIC USE</a></li><li><a href="/atc/J01#J01">J01 &#8212; ANTIBACTERIALS FOR SYSTEMIC USE</a></li><li><a href="/atc/J01F#J01F">J01F &#8212; MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS</a></li><li><a href="/atc/J01FA#J01FA">J01FA &#8212; Macrolides</a></li></ul>S01AA17<ul class="atc-drug-tree"><li><a href="/atc/S#S">S &#8212; SENSORY ORGANS</a></li><li><a href="/atc/S01#S01">S01 &#8212; OPHTHALMOLOGICALS</a></li><li><a href="/atc/S01A#S01A">S01A &#8212; ANTIINFECTIVES</a></li><li><a href="/atc/S01AA#S01AA">S01AA &#8212; Antibiotics</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>34:00.00</li>
<li>08:12.12.04</li>
<li>52:04.04</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00199.pdf?1265922812">show</a>(149 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00199.pdf?1265922748">show</a>(73 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The macrolide, erythromycin, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00802">Alfentanil</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of alfentanil.</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>The macrolide, erythromycin, may increase the effect of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The macrolide, erythromycin, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Erythromycin, a moderate CYP3A4 inhibitor, may increase the effect and toxicity of aprepitant.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin.</td></tr><tr><td><a href="/drugs/DB06237">Avanafil</a></td><td>Co-administration with the moderate CYP3A4 inhibitor erythromycin resulted in an approximate 3.6-fold increase in AUC0-inf and 2.0-fold increase in Cmax of avanafil.
</td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Decreases metabolism, thus decreasing the effects of bendamustine. </td></tr><tr><td><a href="/drugs/DB01158">Bretylium</a></td><td>Increased risk of cardiotoxicity and arryhthmias</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Erythromcyin may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if erythromycin is initiated, discontinued or dose changed. Dosage adjustments may be required. </td></tr><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>Erythromycin increases serum levels of bromocriptine</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of buspirone.</td></tr><tr><td><a href="/drugs/DB00248">Cabergoline</a></td><td>Erythromycin increases serum levels and toxicity of cabergoline</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>The macrolide, erythromycin, may increase the effect of carbamazepine.</td></tr><tr><td><a href="/drugs/DB00439">Cerivastatin</a></td><td>The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin.</td></tr><tr><td><a href="/drugs/DB01166">Cilostazol</a></td><td>Erythromycin increases the effect of cilostazol</td></tr><tr><td><a href="/drugs/DB01012">Cinacalcet</a></td><td>The macrolide, erythromycin, may increase the serum concentration and toxicity of cinacalcet.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Erythromycin increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Severe colchicine toxicity can occur</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The macrolide, erythromycin, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>The macrolide, erythromycin, may increase the effect of the benzodiazepine, diazepam.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The macrolide, erythromycin, may increase the anticoagulant effect of dicumarol..</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients.</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01248">Docetaxel</a></td><td>Erythromycin may increase the serum levels and toxicity of docetaxel.</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, dyphylline.</td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of eletriptan.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.</td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of eplerenone</td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00530">Erlotinib</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB01590">Everolimus</a></td><td>The macrolide, erythromycin, may increase the serum concentration and toxicity of everolimus.</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>Erythromycin increases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of gefitinib</td></tr><tr><td><a href="/drugs/DB00365">Grepafloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>The macrolide, erythromycin, may increase the serum concentration of imatinib.</td></tr><tr><td><a href="/drugs/DB05039">Indacaterol</a></td><td>Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of itraconazole.</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction. </td></tr><tr><td><a href="/drugs/DB01137">Levofloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01627">Lincomycin</a></td><td>Possible antagonism of action with this combination.</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The macrolide, erythromycin, may increase the effect of corticosteroid, methylprednisolone.</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>The macrolide, erythromycin, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00218">Moxifloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB08860">Pitavastatin</a></td><td>Erythromycin decreases metabolism of pitavastatin. Do not exceed 1 mg per day of pitavastatin or use alternative therapy. </td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of quetiapine.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Increased levels of ranolazine - risk of toxicity</td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>The macrolide, erythromycin, may increase the effect of repaglinide.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Increased toxicity of both agents</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Increases roflumilast levels. </td></tr><tr><td><a href="/drugs/DB06335">Saxagliptin</a></td><td>Erythromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. </td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Erythromycin increases the effect and toxicity of sibutramine</td></tr><tr><td><a href="/drugs/DB00203">Sildenafil</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of sildenafil.</td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Erythromycin is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>The macrolide, erythromycin, may increase the toxicity of the statin, simvastatin.</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>The macrolide, erythromycin, may increase the serum concentration of sirolimus.</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01208">Sparfloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, erythromycin, may also increase the blood concentration of tacrolimus.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Erythromycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erythromycin if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of theophylline.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Erythromycin is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Erythromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>The macrolide, erythromycin, may increase the effect of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00313">Valproic Acid</a></td><td>The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Erythromycin, a moderate CYP3A4 inhibitor, may reduce the metabolism and clearance of vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of vardenafil if erythromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Erythromycin, a moderate CYP3A4 inhibitor, may increase the serum concentration of veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of verapamil if erythromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of vinblastine if erythromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Erythromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Erythromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08828">Vismodegib</a></td><td>P-glycoprotein inhibitors may increase the chance of adverse drug reactions. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erythromycin by decreasing its metabolism. Erythromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The macrolide, erythromycin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00549">Zafirlukast</a></td><td>Erythromycin may decrease the serum concentration and effect of zafirlukast.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01198">Zopiclone</a></td><td>The macrolide antibiotic, erythromycin, may increase the serum concentration of zopiclone. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if erythromycin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take on empty stomach: 1 hour before or 2 hours after meals.</li>
<li>Take with a full glass of water Avoid taking with grapefruit juice.</li></ul></td></tr></tbody></table>